Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Figure 3
Overall survival curves in the imatinib plus BSC group (solid line) and the BSC alone group (dotted line). Median overall survival times were 22 months and 4 months, respectively. The hazard ratio for imatinib plus BSC was 0.332 (, log-rank test). BSC, best supportive care.